Evaluating the effectiveness of amphotericin B and azoles for invasive fungal infections
Official title: A Retrospective Clinical Study on the Efficacy and Safety of Amphotericin B Compared With Azoles in the Treatment of Invasive Fungal Disease
Run by Sichuan Provincial People's Hospital · NCT06819410 · Data updated 2026-11-12
This study looks at how well amphotericin B and azole antifungals work and how safe they are for patients with invasive fungal infections based on their medical records.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 1000 (estimated) |
| Sponsor | Sichuan Provincial People's Hospital Academic / other |
| Locations | 1 site (Chengdu, Sichuan) |
| Status | Recruiting |
| Started | May 1, 2021 |
| Main results expected | February 1, 2025 |
| Study ends | February 1, 2025 |
| Registry record updated | February 11, 2025 |
| Trial ID | NCT06819410 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are patients of any age or gender who have been diagnosed with invasive fungal disease and treated with polyene or azole antifungals for at least 7 days.
✕Probably not a fit
Patients with incomplete data or those deemed unsuitable by the investigator will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study collects and analyzes medical records and clinical data of patients diagnosed with invasive fungal disease who have been treated with amphotericin B or azole antifungals. The data is gathered from the electronic medical record system of Sichuan Provincial People's Hospital over a period from 2021 to 2024. The primary focus is to assess the efficacy and safety of these antifungal treatments in real-world clinical settings.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the most effective treatment options for invasive fungal infections, potentially improving patient outcomes.
How similar studies have gone: While this study focuses on a specific patient population and treatment regimen, similar studies evaluating antifungal therapies have shown promising results in improving treatment outcomes.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * There is no age limit, gender is not limited * Patients with invasive fungal disease who are treated with polyene antifungals or azole antifungals should be treated for ≥ 7 days. Exclusion Criteria: * Patients with incomplete data or other factors affecting the clinical outcome judgement * Patients who are judged by the investigator to be unsuitable to participate in this study.
Where it's running
-
Sichuan Provincial People's Hospital
Chengdu, Sichuan, China Recruiting
Study contacts
- Study coordinator: lingai Pan, PhD
- Email: panlingai2004@163.com
- Phone: 17708130236
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Tracking invasive fungal infections after allogeneic hematopoietic stem cell transplant
We will follow people who had an allogeneic stem cell transplant to see how often serious fungal infections occur and which clinical factors predict them.
-
Treating breakthrough invasive fungal infections in blood cancer patients with liposomal amphotericin B versus isavuconazole/posaconazole
This project will test whether liposomal amphotericin B or isavuconazole/posaconazole works better and is safer for adults with blood cancers who develop breakthrough invasive fungal infections after antifungal prophylaxis.
-
Immune monitoring during invasive mold infections.
This project will test whether tracking T-cell immune checkpoints can identify adults with invasive mold infections who might benefit from adding immunotherapy to antifungal treatment.
-
Global registry for emerging invasive fungal infections
This study is collecting information about invasive fungal infections to better understand how they spread, how they are diagnosed, and how well different treatments work for people affected by them.
-
Low-dose Liposomal Amphotericin B for preventing fungal infections in adults with blood cancers and prolonged neutropenia
This study tests whether giving a daily 50 mg dose of liposomal amphotericin B can help prevent invasive fungal infections in adults with blood cancers who have prolonged low white blood cell counts.
-
Low-dose liposomal amphotericin B to prevent invasive fungal infections in neutropenic children
This study tests whether giving a fixed low dose of liposomal amphotericin B can prevent invasive fungal infections in children aged 3–17 who are severely neutropenic after hematopoietic stem cell transplantation or similar high-risk conditions.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.